1. Market Research
  2. > Biotechnology
  3. > Biological Therapy Market Trends
  4. > B-Cell Leukemia - Pipeline Review, H2 2013

B-Cell Leukemia - Pipeline Review, H2 2013

  • July 2013
  • -
  • Global Markets Direct
  • -
  • 95 pages

B-Cell Leukemia - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'B-Cell Leukemia - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for B-Cell Leukemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for B-Cell Leukemia. B-Cell Leukemia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for B-Cell Leukemia.
- A review of the B-Cell Leukemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the B-Cell Leukemia pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for B-Cell Leukemia.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding B-Cell Leukemia pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

B-Cell Leukemia - Pipeline Review, H2 2013
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
B-Cell Leukemia Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for B-Cell Leukemia 10
B-Cell Leukemia Therapeutics under Development by Companies 12
B-Cell Leukemia Therapeutics under Investigation by Universities/Institutes 14
Late Stage Products 15
Comparative Analysis 15
Mid Clinical Stage Products 16
Comparative Analysis 16
Early Clinical Stage Products 17
Comparative Analysis 17
Discovery and Pre-Clinical Stage Products 18
Comparative Analysis 18
B-Cell Leukemia Therapeutics - Products under Development by Companies 19
B-Cell Leukemia Therapeutics - Products under Investigation by Universities/Institutes 20
Companies Involved in B-Cell Leukemia Therapeutics Development 21
Bristol-Myers Squibb Company 21
Amgen Inc. 22
MedImmune LLC 23
Lentigen Corporation 24
Glenmark Pharmaceuticals Ltd. 25
GTC Biotherapeutics, Inc. 26
Nippon Shinyaku Co., Ltd. 27
Ono Pharmaceutical Co., Ltd. 28
Portola Pharmaceuticals, Inc. 29
Mundipharma International Limited 30
Cellectis S.A. 31
Celentyx Ltd. 32
Stemline Therapeutics, Inc. 33
Xencor, Inc. 34
SBI Biotech Co., Ltd. 35
Inserm Transfert SA 36
Advancell 37
B-Cell Leukemia - Therapeutics Assessment 38
Assessment by Monotherapy Products 38
Assessment by Combination Products 39
Assessment by Route of Administration 40
Assessment by Molecule Type 43
Drug Profiles 46
moxetumomab pasudotox - Drug Profile 46
Product Description 46
Mechanism of Action 46
RandD Progress 46
acadesine - Drug Profile 48
Product Description 48
Mechanism of Action 48
RandD Progress 48
bafetinib - Drug Profile 50
Product Description 50
Mechanism of Action 50
RandD Progress 50
forodesine hydrochloride - Drug Profile 52
Product Description 52
Mechanism of Action 52
RandD Progress 52
TG-20 - Drug Profile 54
Product Description 54
Mechanism of Action 54
RandD Progress 54
BMS-936564 - Drug Profile 55
Product Description 55
Mechanism of Action 55
RandD Progress 55
XmAb-5485 - Drug Profile 56
Product Description 56
Mechanism of Action 56
RandD Progress 56
Photochemically Inactivated EBV Infected B Cell Vaccine - Drug Profile 57
Product Description 57
Mechanism of Action 57
RandD Progress 57
HGC-1 - Drug Profile 58
Product Description 58
Mechanism of Action 58
RandD Progress 58
Autologous CD19 Specific T-cell Infusion + [cyclophosphamide] + [fludarabine phosphate] + Leukapheresis - Drug Profile 59
Product Description 59
Mechanism of Action 59
RandD Progress 59
GNKG-168 - Drug Profile 60
Product Description 60
Mechanism of Action 60
RandD Progress 60
Anti-Tac(Fv)-PE38 Immunotoxin - Drug Profile 62
Product Description 62
Mechanism of Action 62
RandD Progress 62
Vivia-009 - Drug Profile 64
Product Description 64
Mechanism of Action 64
RandD Progress 64
GBR-401 - Drug Profile 65
Product Description 65
Mechanism of Action 65
RandD Progress 65
PRT-2070 - Drug Profile 66
Product Description 66
Mechanism of Action 66
RandD Progress 66
Lenaldekar - Drug Profile 67
Product Description 67
Mechanism of Action 67
RandD Progress 67
ONO-4059 - Drug Profile 68
Product Description 68
Mechanism of Action 68
RandD Progress 68
Anti-CD19-CAR-Transduced T Cells - Drug Profile 69
Product Description 69
Mechanism of Action 69
RandD Progress 69
rituximab Biosimilar - Drug Profile 70
Product Description 70
Mechanism of Action 70
RandD Progress 70
Tumor-Derived Lymphocytes + Allogeneic Hematopoietic Stem Cell Transplantation - Drug Profile 71
Product Description 71
Mechanism of Action 71
RandD Progress 71
Anti-APRIL - Drug Profile 72
Product Description 72
Mechanism of Action 72
RandD Progress 72
LG-740 - Drug Profile 73
Product Description 73
Mechanism of Action 73
RandD Progress 73
interferon alfa-2b biosimilar - Drug Profile 74
Product Description 74
Mechanism of Action 74
RandD Progress 74
Anti-Cancer Program - Drug Profile 75
Product Description 75
Mechanism of Action 75
RandD Progress 75
Xanthone Derivatives For Cancer - Drug Profile 76
Product Description 76
Mechanism of Action 76
RandD Progress 76
TAB-08 - Drug Profile 77
Product Description 77
Mechanism of Action 77
RandD Progress 77
L1AD3 - Drug Profile 79
Product Description 79
Mechanism of Action 79
RandD Progress 79
B-Cell Leukemia Therapeutics - Drug Profile Updates 80
B-Cell Leukemia Therapeutics - Discontinued Products 84
B-Cell Leukemia Therapeutics - Dormant Products 85
B-Cell Leukemia - Product Development Milestones 86
Featured News and Press Releases 86
Jun 17, 2013: TG Therapeutics Presents Clinical Poster Presentations On TG-1101 At EHA Meeting 86
May 16, 2013: AstraZeneca's MedImmune Enrolls First Patient In Phase III Leukemia Trial Of Moxetumomab Pasudotox 86
Apr 26, 2013: MorphoSys Initiates Phase II Study Of Anti-CD19 Antibody MOR208 In B-cell Acute Lymphoblastic Leukemia 87
Dec 10, 2012: Onconova Presents Positive Clinical Results Of Rigosertib At ASH Meeting 87
Nov 05, 2012: Emergent BioSolutions To Present Data On TRU-016 And Bendamustine Combination Therapy At ASH Annual Meeting 2012 89
Nov 05, 2012: Emergent BioSolutions To Present Phase Ib Data Of TRU-016 In Combination With Rituximab And Bendamustine At ASH Annual Meeting 2012 90
Aug 24, 2012: TG Therapeutics Announces Poster Presentation For Ublituximab At 7th International Workshop On Waldenstrom's Macroglobulinemia 91
Dec 12, 2011: CytRx Announces Presentation Of Favorable Phase II Results With Bafetinib In Relapsed B-Cell Chronic Lymphocytic Leukemia At ASH Conference 91
Jun 04, 2007: ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial In B-Cell Chronic Lymphocytic Leukemia 92
Appendix 94
Methodology 94
Coverage 94
Secondary Research 94
Primary Research 94
Expert Panel Validation 94
Contact Us 95
Disclaimer 95

List of Tables

Number of Products Under Development for B-Cell Leukemia, H2 2013 10
Products under Development for B-Cell Leukemia - Comparative Analysis, H2 2013 11
Number of Products under Development by Companies, H2 2013 13
Number of Products under Investigation by Universities/Institutes, H2 2013 14
Comparative Analysis by Late Stage Development, H2 2013 15
Comparative Analysis by Mid Clinical Stage Development, H2 2013 16
Comparative Analysis by Early Clinical Stage Development, H2 2013 17
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 18
Products under Development by Companies, H2 2013 19
Products under Investigation by Universities/Institutes, H2 2013 20
Bristol-Myers Squibb Company, H2 2013 21
Amgen Inc., H2 2013 22
MedImmune LLC, H2 2013 23
Lentigen Corporation, H2 2013 24
Glenmark Pharmaceuticals Ltd., H2 2013 25
GTC Biotherapeutics, Inc., H2 2013 26
Nippon Shinyaku Co., Ltd., H2 2013 27
Ono Pharmaceutical Co., Ltd., H2 2013 28
Portola Pharmaceuticals, Inc., H2 2013 29
Mundipharma International Limited, H2 2013 30
Cellectis S.A., H2 2013 31
Celentyx Ltd., H2 2013 32
Xencor, Inc., H2 2013 34
SBI Biotech Co., Ltd., H2 2013 35
Inserm Transfert SA, H2 2013 36
Advancell, H2 2013 37
Assessment by Monotherapy Products, H2 2013 38
Assessment by Combination Products, H2 2013 39
Assessment by Stage and Route of Administration, H2 2013 42
Assessment by Stage and Molecule Type, H2 2013 45
B-Cell Leukemia Therapeutics - Drug Profile Updates 80
B-Cell Leukemia Therapeutics - Discontinued Products 84
B-Cell Leukemia Therapeutics - Dormant Products 85

List of Figures

Number of Products under Development for B-Cell Leukemia, H2 2013 10
Products under Development for B-Cell Leukemia - Comparative Analysis, H2 2013 11
Products under Development by Companies, H2 2013 12
Products under Investigation by Universities/Institutes, H2 2013 14
Late Stage Products, H2 2013 15
Mid Clinical Stage Products, H2 2013 16
Early Clinical Stage Products, H2 2013 17
Discovery and Pre-Clinical Stage Products, H2 2013 18
Assessment by Monotherapy Products, H2 2013 38
Assessment by Combination Products, H2 2013 39
Assessment by Route of Administration, H2 2013 40
Assessment by Stage and Route of Administration, H2 2013 41
Assessment by Molecule Type, H2 2013 43
Assessment by Stage and Molecule Type, H2 2013 44

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Hematopoietic Stem Cell Transplantation - Pipeline Review, H2 2016

Hematopoietic Stem Cell Transplantation - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • October 2016
  • by Global Markets Direct

Hematopoietic Stem Cell Transplantation - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hematopoietic Stem Cell Transplantation - ...

MediGene AG - Product Pipeline Review - 2016

MediGene AG - Product Pipeline Review - 2016

  • $ 1500
  • Company report
  • September 2016
  • by Global Markets Direct

MediGene AG - Product Pipeline Review - 2016 Summary Global Markets Direct’s, ‘MediGene AG - Product Pipeline Review - 2016’, provides an overview of the MediGene AG’s pharmaceutical research and ...

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Pipeline Review, H2 2016

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • October 2016
  • by Global Markets Direct

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.